title: Retrospective data collection of psoriasis treatment with fumaric acid esters in children and adolescents in Germany (KIDS FUTURE study).
abstract: BACKGROUND
  Given that there is no standard systemic treatment for children and adolescents with plaque psoriasis, this non-interventional, multicenter, retrospective study collected data on the efficacy and safety of long-term treatment with fumaric acid esters (FAEs) in this particular patient group.
  
  
  METHODS
  In patients younger than 18 years of age at the start of FAE treatment, data on efficacy and safety was retrospectively collected for at least 36 months.
  
  
  RESULTS
  Data from 127 patients (aged 6-17 years) was collected for treatment durations of up to 60 months. Physician's Global Assessment, Psoriasis Area and Severity Index, and Body Surface Area showed marked improvement in the first six months. After 36 months, these parameters had, on average, improved by up to two-thirds of baseline values. Thirty-seven patients experienced at least one adverse event (AE), which was FAE-related in 36 individuals. Three AEs (proteinuria (one case), flushing (two cases)) persisted during the observation period while on treatment. Fifteen AEs led to the discontinuation of therapy; nearly all of these cases were related to gastrointestinal disorders.
  
  
  CONCLUSIONS
  The KIDS FUTURE study - for the first time - included a larger population of children and adolescents with psoriasis who were treated with FAEs. The data obtained suggests that long-term FAE therapy in this patient group may be effective and safe. The results are currently being verified in an ongoing clinical study.
authors.affiliation: Dermatologikum Hamburg, Germany.
authors.forename: Kristian
authors.initials: K
authors.lastname: Reich
authors.affiliation: Dermatology/Allergology Practice, Eltville, Germany.
authors.forename: Christoph
authors.initials: C
authors.lastname: Hartl
authors.affiliation: Department of Dermatology, Venereology, and Allergology of the Ruhr University, Bochum, Germany.
authors.forename: Thilo
authors.initials: T
authors.lastname: Gambichler
authors.affiliation: SCIderm GmbH Hamburg, Germany.
authors.forename: Ina
authors.initials: I
authors.lastname: Zschocke
mesh_terms: D000293:Adolescent; D017677:Age Distribution; D002648:Child; D003879:Dermatologic Agents / Q000008:administration & dosage*; D005260:Female; D005650:Fumarates / Q000008:administration & dosage*; D005858:Germany / Q000453:epidemiology; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D015995:Prevalence; D011565:Psoriasis / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology*; D012189:Retrospective Studies; D012307:Risk Factors; D017678:Sex Distribution; D016896:Treatment Outcome
chemical_list: D003879:Dermatologic Agents; D005650:Fumarates